Stay updated on Timing of Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Timing of Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Timing of Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    New history entry added for 2025-11-25 (Revision: v3.3.2). An older entry (Revision: v3.3.1) was deleted on 2025-11-17.
    Difference
    0.0%
    Check dated 2025-11-28T00:43:24.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Version 3.3.1 (2025-11-17) adds Contacts/Locations and Study Status to the record, replacing version 3.2.0.
    Difference
    0.0%
    Check dated 2025-11-20T23:13:47.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Removed the government funding status notice from the page. The rest of the study history and content remain unchanged.
    Difference
    0.0%
    Check dated 2025-11-13T17:12:10.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Version 678 was posted on 2025-10-28 and adds updates to Study Status and Contacts/Locations, while a deletion occurred on 2025-10-20.
    Difference
    0.0%
    Check dated 2025-10-30T11:36:43.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    Update: version revision changed from v3.0.2 to v3.2.0.
    Difference
    0.0%
    Check dated 2025-10-01T05:49:19.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    Update: version from v3.0.2 to v3.1.0, with no other content changes.
    Difference
    0.0%
    Check dated 2025-09-30T03:45:02.000Z thumbnail image

Stay in the know with updates to Timing of Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Timing of Pembrolizumab in NSCLC Clinical Trial page.